Silo Pharma, Inc.
SILO · XNASCIK 1514183fmd_096VDTS57HNVB6JH83CYGDA0WXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Jun 30, 2026, 50 periods
| Line item | FY2013 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 0 | 0 | – | 0 | 0 | 0 | 0 |
| Total interest income | – | – | – | – | – | 0 | 0 | – | – | – |
| Cost of revenue | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net interest income | – | – | – | – | – | (0) | 0 | – | – | – |
| Realized investment gains (losses) | 0 | (0) | (0) | 0 | – | 7 | (0) | – | (0) | 0 |
| Gross profit | – | – | – | 0 | (0) | 0 | 0 | 0 | 0 | 0 |
| Research and development | – | – | – | – | 0 | 1 | 1 | 1 | 2 | 2 |
| Selling, general and administrative | – | – | – | – | 0 | 0 | 0 | 0 | – | – |
| Total operating expenses | – | 0 | 1 | 1 | 2 | 3 | 4 | 4 | 5 | 4 |
| Operating income | – | (0) | (1) | (1) | (2) | (3) | (4) | (4) | (5) | (4) |
| Interest expense | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | – | – | – | – | – | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | – | 1 | (0) | (0) | (0) | 7 | (0) | 0 | 0 | 0 |
| Income before taxes | – | – | – | – | (3) | 4 | (4) | (4) | (4) | (4) |
| Income tax expense | – | – | – | – | – | 0 | – | – | – | – |
| Net income from continuing operations | – | – | – | – | (3) | 3 | (4) | (4) | (4) | – |
| Net income | – | 0 | (1) | (1) | (3) | 4 | (4) | (4) | (4) | (4) |
| Net income to common shareholders | – | – | – | (1) | (3) | 2 | (4) | – | – | – |